Nasuh C Buyukkaramikli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3363772/publications.pdf

Version: 2024-02-01

23 papers 492 citations

840776 11 h-index 713466 21 g-index

23 all docs 23 docs citations

times ranked

23

746 citing authors

#	Article	IF	Citations
1	Constrained Optimization Methods in Health Services Research—An Introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force. Value in Health, 2017, 20, 310-319.	0.3	79
2	Cost-Effectiveness Analysis in Telehealth: A Comparison between Home Telemonitoring, Nurse Telephone Support, and Usual Care in Chronic Heart Failure Management. Value in Health, 2018, 21, 772-782.	0.3	69
3	Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigmâ,,¢ Veo system and the Vibeâ,,¢ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation. Health Technology Assessment, 2016. 20. 1-252.	2.8	57
4	Severity-Adjusted Probability of Being Cost Effective. Pharmacoeconomics, 2019, 37, 1155-1163.	3.3	50
5	Application of Constrained Optimization Methods in Health Services Research: Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force. Value in Health, 2018, 21, 1019-1028.	0.3	36
6	TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility. Pharmacoeconomics, 2019, 37, 1391-1408.	3.3	33
7	Coordinated Logistics: Joint Replenishment with Capacitated Transportation for a Supply Chain. Production and Operations Management, 2014, 23, 110-126.	3.8	29
8	Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2017, 35, 1211-1221.	3.3	21
9	Integrating inventory control and capacity management at a maintenance service provider. Annals of Operations Research, 2015, 231, 185-206.	4.1	17
10	Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat ^{\hat{A}^{\otimes}} fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Therapeutic Advances in Respiratory Disease, 2016, 10, 391-401.	2.6	15
11	EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties. Applied Health Economics and Health Policy, 2018, 16, 429-432.	2.1	12
12	10 Years of End-of-Life Criteria in the United Kingdom. Value in Health, 2021, 24, 691-698.	0.3	12
13	Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2020, 24, 1-220.	2.8	12
14	Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal. Pharmacoeconomics, 2018, 36, 145-159.	3.3	10
15	Periodic capacity management under a lead-time performance constraint. OR Spectrum, 2013, 35, 221-249.	3.4	9
16	Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2019, 37, 141-153.	3.3	8
17	Flexible hiring in a make to order system with parallel processing units. Annals of Operations Research, 2013, 209, 159-178.	4.1	6
18	The Methodological Quality and Challenges in Conducting Economic Evaluations of Newborn Screening: A Scoping Review. International Journal of Neonatal Screening, 2020, 6, 94.	3.2	6

#	Article	IF	CITATIONS
19	Value of information analysis in telehealth for chronic heart failure management. PLoS ONE, 2019, 14, e0218083.	2.5	5
20	Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma. Pharmacoeconomics, 2019, 37, 975-984.	3.3	3
21	Coordinating failed goods collecting and repair capacity policies in the maintenance of commoditized capital goods. International Journal of Production Economics, 2019, 208, 29-42.	8.9	2
22	A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England. European Journal of Health Economics, 2021, 22, 51-73.	2.8	1
23	Review of Meta-Analysis Methods for Multinomial Data. Value in Health, 2013, 16, A576-A577.	0.3	0